Please use this identifier to cite or link to this item:
Title: Application of advanced mass spectrometry-based proteomics to study hypoxia driven cancer progression
Authors: Vinaiphat, Arada
Low, Jee Keem
Yeoh, Kheng Wei
Chng, Wee Joo
Sze, Siu Kwan
Keywords: Science::Medicine
Issue Date: 2021
Source: Vinaiphat, A., Low, J. K., Yeoh, K. W., Chng, W. J. & Sze, S. K. (2021). Application of advanced mass spectrometry-based proteomics to study hypoxia driven cancer progression. Frontiers in Oncology, 11, 559822-.
Project: MOE2016-T2-2-018
Journal: Frontiers in Oncology
Abstract: Cancer is one of the largest contributors to the burden of chronic disease in the world and is the second leading cause of death globally. It is associated with episodes of low-oxygen stress (hypoxia or ischemia/reperfusion) that promotes cancer progression and therapeutic resistance. Efforts have been made in the past using traditional proteomic approaches to decipher oxygen deprivation stress-related mechanisms of the disease initiation and progression and to identify key proteins as a therapeutic target for the treatment and prevention. Despite the potential benefits of proteomic in translational research for the discovery of new drugs, the therapeutic outcome with this approach has not met expectations in clinical trials. This is mainly due to the disease complexity which possess a multifaceted molecular pathology. Therefore, novel strategies to identify and characterize clinically important sets of modulators and molecular events for multi-target drug discovery are needed. Here, we review important past and current studies on proteomics in cancer with an emphasis on recent pioneered labeling approaches in mass spectrometry (MS)-based systematic quantitative analysis to improve clinical success. We also discuss the results of the selected innovative publications that integrate advanced proteomic technologies (e.g. MALDI-MSI, pSILAC/SILAC/iTRAQ/TMT-LC-MS/MS, MRM-MS) for comprehensive analysis of proteome dynamics in different biosystems, including cell type, cell species, and subcellular proteome (i.e. secretome and chromatome). Finally, we discuss the future direction and challenges in the application of these technological advancements in mass spectrometry within the context of cancer and hypoxia.
ISSN: 2234-943X
DOI: 10.3389/fonc.2021.559822
Schools: School of Biological Sciences 
Rights: © 2021 Vinaiphat, Low, Yeoh, Chng and Sze. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
fonc-11-559822.pdf1.67 MBAdobe PDFThumbnail

Citations 20

Updated on Jun 16, 2024

Web of ScienceTM
Citations 20

Updated on Oct 26, 2023

Page view(s)

Updated on Jun 17, 2024

Download(s) 50

Updated on Jun 17, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.